Merck

Last updated January 31, 2026

124

Innovation Areas

5,362

Inventors

Collaborations

Polysaccharide carrier protein conjugation chemistry: MerckRecent Research Landscape

Serotype-specific immune evasion limits vaccine efficacy across diverse populations. Engineering precise carbohydrate-protein conjugation increases protective breadth and reduces disease burden.

What technical problems is Merck addressing in Polysaccharide carrier protein conjugation chemistry?

Low vaccine immunogenicity

(14)evidences

Ambiguity in distinguishing between closely related Streptococcus pneumoniae serotypes leads to ineffective vaccine formulation and monitoring. Precise differentiation ensures targeted immune responses and reliable epidemiological surveillance.

Low vaccine manufacturing yields

(11)evidences

Inefficient covalent bonding between complex saccharides and carrier proteins limits vaccine yield. Improving coupling rates ensures higher immunogenicity and reduced manufacturing waste.